tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IMAB Stock Latest News

I-Mab Strengthens Leadership with New Board Appointments and R&D Committee Formation
Company AnnouncementsI-Mab Strengthens Leadership with New Board Appointments and R&D Committee Formation
13d ago
6K
IMAB
I-Mab appoints Lenz, Liu to board of directors, forms R&D Committee
PremiumThe Fly
I-Mab appoints Lenz, Liu to board of directors, forms R&D Committee
13d ago
IMAB
I-Mab’s Q2 2025: Clinical Progress and Financial Strength
PremiumCompany Announcements
I-Mab’s Q2 2025: Clinical Progress and Financial Strength
17d ago
IMAB
I-Mab price target raised to $6 from $5 at Needham
PremiumThe Fly
I-Mab price target raised to $6 from $5 at Needham
18d ago
IMAB
I-MAB’s Positive Outlook: Buy Rating Backed by Financial Stability and Promising Clinical Developments
PremiumRatings
I-MAB’s Positive Outlook: Buy Rating Backed by Financial Stability and Promising Clinical Developments
18d ago
IMAB
I-Mab Reports Strong Financials and Clinical Progress in August 2025
PremiumCompany AnnouncementsI-Mab Reports Strong Financials and Clinical Progress in August 2025
18d ago
6K
IMAB
I-Mab reports Q2 EPS (3c), consensus (5c)
Premium
The Fly
I-Mab reports Q2 EPS (3c), consensus (5c)
18d ago
IMAB
I-Mab sees cash runway through 4Q28
Premium
The Fly
I-Mab sees cash runway through 4Q28
18d ago
IMAB
I MAB (ADS) options imply 11.8% move in share price post-earnings
PremiumThe Fly
I MAB (ADS) options imply 11.8% move in share price post-earnings
20d ago
IMAB
I-Mab Completes Enrollment in Phase 1b Study for Givastomig in Gastric Cancer
PremiumCompany Announcements
I-Mab Completes Enrollment in Phase 1b Study for Givastomig in Gastric Cancer
27d ago
6K
IMAB
I-Mab completes enrollment in Phase 1b dose expansion study for givastomig
PremiumThe Fly
I-Mab completes enrollment in Phase 1b dose expansion study for givastomig
27d ago
IMAB
3 Penny Stocks to Watch Now, 8/5/25
PremiumMarket News
3 Penny Stocks to Watch Now, 8/5/25
1M ago
BTAI
IMAB
I-Mab Announces $65 Million ADS Offering to Advance Cancer Treatment Pipeline
PremiumCompany AnnouncementsI-Mab Announces $65 Million ADS Offering to Advance Cancer Treatment Pipeline
1M ago
6K
IMAB
Everest Medicines announces strategic equity investment in I-Mab
Premium
The Fly
Everest Medicines announces strategic equity investment in I-Mab
1M ago
IMAB
I-Mab prices 33.3M ADSs at $1.95 in underwritten offering
Premium
The Fly
I-Mab prices 33.3M ADSs at $1.95 in underwritten offering
1M ago
IMAB
I-MAB Announces Preliminary Financial Results for Mid-2025
PremiumCompany Announcements
I-MAB Announces Preliminary Financial Results for Mid-2025
1M ago
6K
IMAB
I-Mab Acquires Bridge Health to Boost Givastomig Portfolio
PremiumCompany Announcements
I-Mab Acquires Bridge Health to Boost Givastomig Portfolio
2M ago
6K
IMAB
I-Mab entered into agreement to acquire 100% ownership of Bridge Health Biotech
PremiumThe Fly
I-Mab entered into agreement to acquire 100% ownership of Bridge Health Biotech
2M ago
IMAB
I-MAB Amends Prospectus for $21 Million ADS Offering
PremiumCompany Announcements
I-MAB Amends Prospectus for $21 Million ADS Offering
2M ago
6K
IMAB
I-MAB’s Givastomig Shows Promising Efficacy and Safety in Gastric Cancer, Earning Buy Rating
PremiumRatingsI-MAB’s Givastomig Shows Promising Efficacy and Safety in Gastric Cancer, Earning Buy Rating
2M ago
IMAB
Promising Clinical Developments and Strong Performance Drive Buy Rating for I-MAB
Premium
Ratings
Promising Clinical Developments and Strong Performance Drive Buy Rating for I-MAB
2M ago
IMAB
I-Mab Reports Promising Phase 1b Results for Givastomig in Gastric Cancer
Premium
Company Announcements
I-Mab Reports Promising Phase 1b Results for Givastomig in Gastric Cancer
2M ago
6K
IMAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >